Syncona has reported that its portfolio company, Achilles Therapeutics, has finalized an agreement to sell certain technology assets to AstraZeneca. This transaction involves the transfer of the commercial license for data and samples from the TRACERx non-small cell lung cancer research to AstraZeneca. Additionally, AstraZeneca will assume the role of sponsor for Achilles' Material Acquisition Platform. The total compensation AstraZeneca has agreed to pay Achilles for these assets amounts to $12 million.
Following this transaction, Achilles intends to implement further measures, which include reducing its workforce and downsizing its Board of Directors.
The material has been provided by InstaForex Company - www.instaforex.com
Following this transaction, Achilles intends to implement further measures, which include reducing its workforce and downsizing its Board of Directors.
The material has been provided by InstaForex Company - www.instaforex.com